Flemming Ornskov
Shire moves to seal Baxalta deal with improved offer
December 22, 2015Research and Development, Sales and Marketing Baxalta, Flemming Ornskov, Shire
Shire is set to sweeten its $30 billion bid for Baxalta by offering 40% of the total, or $12 billion, …
Shire’s dry eye treatment gets a no – for now
October 19, 2015Sales and Marketing Complete Response Letter, FDA, Flemming Ornskov, Shire, dry eye disease, lifitegrast
Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
